ReviewNPJ precision oncology2018
Universal cancer screening: revolutionary, rational, and realizable.
Review in NPJ precision oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05227261 (Assessment of a Novel Blood Test in Early Detection of the Five Common Cancers Based on the Investigation of the Circulating Tumour DNA), which is not on this map. Cited by 76 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Assessment of a Novel Blood Test in Early Detection of the Five Common Cancers Based on the Investigation of the Circulating Tumour DNA
Who cites it
76 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The diagnostic utility of glycosaminoglycans (GAGs) in the early detection of cancer: a systematic review.PeerJ · 2024Pooled it
- Multi-cancer Detection Using Pattern Formation in Drying Body Fluids: A Systematic Review and Meta-Analysis of Diagnostic Test Accuracy Studies.Technology in cancer research & treatmentPooled it
- Predictors of perceived value of multi-cancer early detection testing: a national PRECEDE-PROCEED framework study.Cancer causes & control : CCC · 2026Article
- Modeled Sojourn Time and Sensitivity for Detecting Preclinical Cancers Retrospectively by a Multicancer Early Detection Test.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2026Article
- Optimizing risk cutoffs in joint endoscopic screening for upper gastrointestinal cancers: a data-driven approach from models to real-world practice.Surgical endoscopy · 2026Article
- S12micro: a machine learning-derived serum miRNA panel for high-performance pan-cancer diagnosis via liquid biopsy.International journal of surgery (London, England) · 2026Article
- Exploration of multi-omics liquid biopsy approaches for multi-cancer early detection: The PROMISE study.Innovation (Cambridge (Mass.)) · 2026Article
- Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus-associated oropharynx cancer early detection.Journal of the National Cancer Institute · 2026Article
- Detection of Prostate Carcinoma in an Asymptomatic Individual Initiated by an Immunological Biopsy-A Case Report.Oncology research · 2026Article
- Unlocking the Translational Potential of Nanophotonic Biosensors: Perspectives on Application-Guided Design.ACS photonics · 2025Review
- From Combination Early Detection to Multicancer Testing: Shifting Cancer Care toward Proactive Prevention and Interception.Cancer prevention research (Philadelphia, Pa.) · 2025Review
- Primary Care Clinician Preferences and Perspectives on Multi-Cancer Detection Testing Across an Integrated Healthcare System.Journal of personalized medicine · 2025Article
- Liquid biopsy-based multi-cancer early detection: an exploration road from evidence to implementation.Science bulletin · 2025Review
- Clinical Evaluation of Cancer Signal Origin Prediction and Diagnostic Resolution following Multicancer Early Detection Testing in the PATHFINDER Study.Cancer prevention research (Philadelphia, Pa.) · 2025Article
- Incidental vs. symptomatic diagnosis of follicular lymphoma: implications of earlier detection.Blood cancer journal · 2025Article
- Diagnostic value of the wnt target and cancer-associated blood biomarker hPG80: ONCOPRO case-control prospective study.Biomarker research · 2025Article
- Navigating Complexity: Perspectives on Risk Assessment in the Era of New Blood-Based Tests for Early Cancer Detection.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- Article
- Are Non-invasive Multi-cancer Early Cancer Detection Tests the Future?Digestive diseases and sciences · 2025Review
- Multicancer early detection testing: Guidance for primary care discussions with patients.Cancer · 2025Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer remains the second leading cause of mortality worldwide, and overall cancer-related deaths are increasing. Despite the survival benefit from early detection, screening has to date targeted only those few organs that harbor tumors of sufficient prevalence to show cost-effectiveness at population levels, leaving most cancer types unscreened. In this perspective overview, a case is made for universal cancer screening as a logical and more inclusive approach with potentially high impact. The centrally important conceptual drivers to universal screening are biological and epidemiological. The shared biology of tumor marker release into a common distant medium, like blood, can be exploited for multi-cancer detection from a single test. And, by aggregating prevalence rates, universal screening allows all cancers (including less common ones) to be included as targets, increases screening efficiency and integration across tumor types, and potentially improves cost-effectiveness over single-organ approaches. The identification of new tumor marker classes with both broad expression across tumor types and site-prediction, remarkable advances in assay technologies, and compelling early clinical data increase the likelihood of actualizing this new paradigm. Multi-organ screening could be achieved by targeting markers within or stemming from the circulation (including blood, urine, saliva, and expired breath) or those exfoliated into common excretory pathways (including the gastrointestinal and female reproductive tracts). Rigorous clinical studies in intended use populations and collaborations between academia, industry, professional societies, and government will be required to bring this lofty vision to a population application.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.